|
1
|
Chen Y, Wang TT, Du J, Li YC, Wang X, Zhou
Y, Yu XX, Fan WM, Zhu QJ, Tong XM and Wang Y: The critical role of
PTEN/PI3K/AKT signaling pathway in shikonin-induced apoptosis and
proliferation inhibition of chronic myeloid leukemia. Cell Physiol
Biochem. 47:981–993. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kaleem B, Shahab S, Ahmed N and Shamsi TS:
Chronic myeloid leukemia-prognostic value of mutations. Asian Pac J
Cancer Prev. 16:7415–7423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu CJ, Gorantla SP, Müller-Rudorf A,
Muller TA, Kreutmair S, Albers C, Jakob L, Lippert LJ, Yue ZY,
Engelhardt M, et al: Phosphorylation of BECLIN-1 by BCR-ABL
suppresses autophagy in chronic myeloid leukemia. Haematologica.
105:1285–1293. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yin XL, Zhou MR, Fu Y, Yang L, Xu M, Sun
T, Wang XM, Huang T and Chen CY: Histone demethylase RBP2 mediates
the blast crisis of chronic myeloid leukemia through an
RBP2/PTEN/BCR-ABL cascade. Cell Signal. 63:1093602019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Valencia-Serna J, Kucharski C, Chen M,
Remant KC, Jiang XY, Brandwein J and Uludag H: siRNA-mediated
BCR-ABL silencing in primary chronic myeloid leukemia cells using
lipopolymers. J Control Release. 310:141–154. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Burslem GM, Schultz AR, Bondeson DP, Eide
CA, Stevens SL, Druker BJ and Crews CM: Targeting BCR-ABL1 in
chronic myeloid leukemia by PROTAC-mediated targeted protein
degradation. Cancer Res. 79:4744–4753. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bugler J, Kinstrie R, Scott MT and Vetrie
D: Epigenetic reprogramming and emerging epigenetic therapies in
CML. Front Cell Dev Biol. 7:1362019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De Rosa V, Monti M, Terlizzi C, Fonti R,
Del Vecchio S and Iommelli F: Coordinate modulation of glycolytic
enzymes and OXPHOS by imatinib in BCR-ABL driven chronic
myelogenous leukemia cells. Int J Mol Sci. 20:31342019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang XF, Yang JL, Guo GJ, Feng RY, Chen K,
Liao Y, Zhang LF, Sun LP, Huang SL and Chen JL: Novel lncRNA-IUR
suppresses Bcr-Abl-induced tumorigenesis through regulation of
STAT5-CD71 pathway. Mol Cancer. 18:842019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu ZW, Yang C, Wen LL, Liu L, Zuo XB,
Zhou FS, Gao JP, Zheng XD, Shi YJ, Zhu CH, et al: Bach2 regulates
aberrant activation of B cell in systemic lupus erythematosus and
can be negatively regulated by BCR-ABL/PI3K. Exp Cell Res.
365:138–144. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kumar H, Chattopadhyay S, Das N, Shree S,
Patel D, Mohapatra J, Gurjar A, Kushwaha S, Singh AK, Dubey S, et
al: Leprosy drug clofazimine activates peroxisome
proliferator-activated receptor-γ and synergizes with imatinib to
inhibit chronic myeloid leukemia cells. Haematologica. 105:971–986.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carter BZ, Mak PY, Mu H, Wang XM, Tao WJ,
Mak DH, Dettman EJ, Cardone M, Zernovak O, Seki T and Andreeff M:
Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets
chronic myeloid leukemia stem/progenitor cells in a murine model.
Haematologica. 105:1274–1284. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miura M: Therapeutic drug monitoring of
imatinib, nilotinib, and dasatinib for patients with chronic
myeloid leukemia. Biol Pharm Bull. 38:645–654. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huguet F, Cayuela JM, Cambier N,
Carpentier N, Tindel M, Violet I, Zunic P, Lascaux A, Etienne G and
AdheRMC Investigators: Nilotinib efficacy, safety, adherence and
impact on quality of life in newly diagnosed patients with chronic
myeloid leukaemia in chronic phase: A prospective observational
study in daily clinical practice. Br J Haematol. 187:615–626. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Minson AG, Cummins K, Fox L, Costello B,
Yeung D, Cleary R, Forsyth C, Tatarczuch M, Burbury K, Motorna O,
et al: The natural history of vascular and other complications in
patients treated with nilotinib for chronic myeloid leukemia. Blood
Adv. 3:1084–1091. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pan X, Wang F, Zhang Y, Gao HP, Hu ZG,
Wang SC and Zhang J: Design, synthesis and biological activities of
Nilotinib derivates as antitumor agents. Bioorg Med Chem.
21:2527–2534. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Braun TP, Eide CA and Druker BJ: Response
and resistance to BCR-ABL1-targeted therapies. Cancer Cell.
37:530–542. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Clapper E, Wang S, Raninga PV, Di Trapani
G and Tonissen KF: Cross-talk between Bcr-abl and the thioredoxin
system in chronic myeloid leukaemia: Implications for CML
treatment. Antioxidants (Basel). 9:2072020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maiti A, Franquiz MJ, Ravandi F, Cortes
JE, Jabbour EJ, Sasaki K, Marx K, Daver NG, Kadia TM, Konopleva MY,
et al: Venetoclax and BCR-ABL tyrosine kinase inhibitor
combinations: Outcome in patients with philadelphia
chromosome-positive advanced myeloid leukemias. Acta Haematol.
14:1–7. 2020.
|
|
20
|
Sun H, Kapuria V, Peterson LF, Fang DX,
Bornmann WG, Bartholomeusz G, Talpaz M and Donato NJ: Bcr-Abl
ubiquitination and Usp9× inhibition block kinase signaling and
promote CML cell apoptosis. Blood. 117:3151–3162. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu M, Yang L, Shi XP, Gong ZY, Yu RZ,
Zhang DD, Zhang YM and Ma WN: TPD7 inhibits the growth of cutaneous
T cell lymphoma H9 cell through regulating IL-2R signalling
pathway. J Cell Mol Med. 24:984–995. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Steelman LS, Pohnert SC, Shelton JG,
Franklin RA, Bertrand FE and McCubrey JA: JAK/STAT, Raf/MEK/ERK,
PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.
Leukemia. 18:189–218. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rangatia J and Bonnet D: Transient or
long-term silencing of BCR-ABL alone induces cell cycle and
proliferation arrest, apoptosis and differentiation. Leukemia.
20:68–76. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fathi E, Farahzadi R, Valipour B and
Sanaat Z: Cytokines secreted from bone marrow derived mesenchymal
stem cells promote apoptosis and change cell cycle distribution of
K562 cell line as clinical agent in cell transplantation. PLoS One.
14:e02156782019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen CW, Lee YL, Liou JP, Liu YH, Liu CW,
Chen TY and Huang HM: A novel tubulin polymerization inhibitor,
MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in
imatinib-sensitive and imatinib-resistant CML cells. Apoptosis.
21:1008–1018. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Moriyama K and Hori T: BCR-ABL induces
tyrosine phosphorylation of YAP leading to expression of Survivin
and Cyclin D1 in chronic myeloid leukemia cells. Int J Hematol.
110:591–598. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma L, Xu Z, Wang J, Zhu ZC, Lin GB, Jiang
LJ, Lu XZ and Zou C: Matrine inhibits BCR/ABL mediated ERK/MAPK
pathway in human leukemia cells. Oncotarget. 8:108880–108889. 2017.
View Article : Google Scholar : PubMed/NCBI
|
